OncoMatch/Clinical Trials/NCT05701488
SIRT With Tremelimumab and Durvalumab for Resectable HCC
Is NCT05701488 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Durvalumab and Tremelimumab for resectable hepatocellular carcinoma.
Treatment: Durvalumab · Tremelimumab · SIRT — The goal of this research study is to evaluate the safety and tolerability of tremelimumab and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in participants with resectable hepatocellular carcinoma (HCC) who will undergo liver surgery. The names of the interventions involved in this study are: * Durvalumab (a type of immunotherapy) * Tremelimumab (a type of immunotherapy) * Selective Internal Yttrium-90 Radioembolization (SIRT) (a type of radiation microsphere bead)
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage IA, IB, II, IIIA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: any prior treatment for hcc
Lab requirements
Blood counts
hemoglobin ≥ 9.0 g/dl; absolute neutrophil count (anc) ≥ 1,000 /mcl; platelets ≥ 80,000 /mcl
Kidney function
measured creatinine clearance > 40 ml/min by 24-hour urine collection, or calculated creatinine clearance (cl) > 40 ml/min by the cockcroft-gault formula
Liver function
total bilirubin ≤ 2.0 mg/dl; ast (sgot) and alt (sgpt) ≤ 2.5 × institutional upper limit of normal (uln); preserved liver function (child a)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Cedars-Sinai Medical Center · Los Angeles, California
- Beth Israel Deaconess Medical Center · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify